Total Payments
$123,008
2024 Payments
$14,186
Companies
52
Transactions
604
Medicare Patients
1,524
Medicare Billing
$274,032
Payment Breakdown by Category
Other$93,723 (76.2%)
Food & Beverage$13,921 (11.3%)
Travel$7,859 (6.4%)
Consulting$7,010 (5.7%)
Education$495.72 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,223 | 52 | 75.0% |
| Food and Beverage | $13,921 | 499 | 11.3% |
| Travel and Lodging | $7,859 | 31 | 6.4% |
| Consulting Fee | $7,010 | 6 | 5.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,500 | 1 | 1.2% |
| Education | $495.72 | 15 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $83,020 | 173 | $0 (2024) |
| Theravance Biopharma, Inc. | $17,086 | 25 | $0 (2018) |
| Cumberland Pharmaceuticals, Inc. | $3,963 | 11 | $0 (2023) |
| Allergan, Inc. | $3,483 | 35 | $0 (2020) |
| ABBVIE INC. | $3,289 | 35 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,818 | 45 | $0 (2024) |
| Kerecis Limited | $2,409 | 7 | $0 (2024) |
| ViiV Healthcare Company | $1,858 | 102 | $0 (2024) |
| Emergent BioSolutions Inc. | $868.16 | 2 | $0 (2018) |
| Melinta Therapeutics, LLC | $792.18 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,186 | 41 | Gilead Sciences, Inc. ($13,576) |
| 2023 | $20,162 | 102 | Gilead Sciences, Inc. ($18,153) |
| 2022 | $6,283 | 71 | Gilead Sciences, Inc. ($3,695) |
| 2021 | $11,624 | 65 | Gilead Sciences, Inc. ($6,536) |
| 2020 | $13,049 | 39 | Gilead Sciences, Inc. ($9,584) |
| 2019 | $23,151 | 94 | Gilead Sciences, Inc. ($20,481) |
| 2018 | $20,367 | 96 | Gilead Sciences, Inc. ($9,118) |
| 2017 | $14,185 | 96 | Theravance Biopharma Inc. ($8,867) |
All Payment Transactions
604 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: HIV | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $490.00 | General |
| Category: HIV | ||||||
| 12/05/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,450.00 | General |
| 11/26/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $45.10 | General |
| 11/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $121.86 | General |
| 11/13/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/07/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: ANTIBIOTIC | ||||||
| 10/24/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/10/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: GI | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $60.58 | General |
| 09/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: HIV | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $735.00 | General |
| Category: HIV | ||||||
| 08/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.98 | General |
| 07/16/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $52.87 | General |
| 07/10/2024 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 Marigen | Food and Beverage | Cash or cash equivalent | $73.85 | General |
| Category: Wound Care | ||||||
| 06/25/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,450.00 | General |
| 06/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $110.81 | General |
| 05/08/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $43.68 | General |
| Category: HIV | ||||||
| 04/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $53.19 | General |
| 04/11/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: HIV | ||||||
| 04/08/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| Category: HIV | ||||||
| 04/02/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| Category: HIV | ||||||
| 04/02/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Infections and Infectious Diseases | ||||||
| 03/22/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 291 | 545 | $173,205 | $49,067 |
| 2022 | 8 | 327 | 565 | $176,890 | $52,769 |
| 2021 | 11 | 399 | 836 | $264,755 | $79,734 |
| 2020 | 13 | 507 | 1,009 | $302,120 | $92,463 |
Total Patients
1,524
Total Services
2,955
Medicare Billing
$274,032
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 34 | 81 | $50,805 | $13,788 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 86 | 189 | $36,365 | $12,028 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 27 | 95 | $24,115 | $4,933 | 20.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 48 | $13,340 | $4,596 | 34.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 44 | $13,960 | $4,532 | 32.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 32 | $15,900 | $4,465 | 28.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 29 | $10,545 | $2,932 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $5,445 | $1,393 | 25.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 12 | 14 | $2,730 | $399.84 | 14.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 42 | 102 | $56,610 | $17,853 | 31.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 85 | 174 | $31,320 | $9,835 | 31.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 45 | 47 | $16,215 | $4,974 | 30.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 59 | $15,045 | $4,749 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 47 | $13,630 | $4,472 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 28 | 72 | $19,800 | $3,885 | 19.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $10,695 | $3,485 | 32.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 20 | 20 | $7,800 | $2,193 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 21 | $5,775 | $1,324 | 22.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 50 | 157 | $87,135 | $27,628 | 31.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 112 | 220 | $39,600 | $12,720 | 32.1% |
| 99183 | Management and supervision of oxygen chamber therapy per session | Facility | 2021 | 19 | 92 | $30,820 | $8,125 | 26.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 57 | 87 | $22,185 | $7,191 | 32.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 28 | 99 | $27,225 | $5,429 | 19.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 54 | $15,660 | $5,134 | 32.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 26 | $12,090 | $4,198 | 34.7% |
About Dr. Adam Bressler, M.D
Dr. Adam Bressler, M.D is a Infectious Disease healthcare provider based in Gainesville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154371870.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Bressler, M.D has received a total of $123,008 in payments from pharmaceutical and medical device companies, with $14,186 received in 2024. These payments were reported across 604 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($92,223).
As a Medicare-enrolled provider, Bressler has provided services to 1,524 Medicare beneficiaries, totaling 2,955 services with total Medicare billing of $274,032. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Gainesville, GA
- Active Since 05/11/2006
- Last Updated 05/17/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1154371870
Products in Payments
- Biktarvy (Drug) $39,342
- VIBATIV (Drug) $20,815
- Sunlenca (Drug) $8,265
- AVYCAZ (Drug) $3,340
- DALVANCE (Drug) $2,811
- DIFICID (Drug) $2,146
- Genvoya (Drug) $1,636
- Kerecis Omega3 Wound (Device) $1,086
- Baxdela (Drug) $644.79
- DOVATO (Drug) $513.86
- CABENUVA (Biological) $359.66
- TRIUMEQ (Drug) $326.62
- MAVYRET (Drug) $300.42
- ISENTRESS (Drug) $229.88
- Symtuza (Drug) $221.53
- Fetroja (Drug) $202.43
- SYMTUZA (Drug) $175.44
- Arikayce (Drug) $170.16
- JULUCA (Drug) $154.83
- Kerecis Omega3 SurgiClose (Device) $152.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Gainesville
Lennox Archibald, Md, MD
Infectious Disease — Payments: $2.9M
Infectious Disease $2.9M
Dr. Cornelius Clancy, Md, MD
Infectious Disease — Payments: $166,876
Infectious Disease $166,876
Wendy Garlington, Md, MD
Infectious Disease — Payments: $1,427
Infectious Disease $1,427
Gary Wang, Md, Phd, MD, PHD
Infectious Disease — Payments: $850.64
Infectious Disease $850.64
Marie Kima, M.d, M.D
Infectious Disease — Payments: $749.97
Infectious Disease $749.97
Dr. Guy El Helou, M.d, M.D
Infectious Disease — Payments: $656.94
Infectious Disease $656.94